

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the present application.

**Listing of Claims:**

1. (Currently Amended) An activated foam made of a natural or synthetic rubber or a synthetic resin, wherein said foam contains a zirconium compound and/or a germanium compound, and ~~[[has]]~~ comprises cells with a closed-cell structure, and further wherein said foam ~~is used so as to~~ contacts directly or indirectly ~~contact~~ with a human body when a pharmaceutical agent is administered at the same time.

2. (Currently Amended) An activated foam made of a natural or synthetic rubber or a synthetic resin, wherein said foam contains a zirconium compound and/or a germanium compound and carbon, and ~~[[has]]~~ comprises cells with a closed-cell structure, and further wherein said foam ~~is used so as to~~ contacts directly or indirectly ~~contact~~ with a human body when a pharmaceutical agent is administered at the same time.

3. (Previously Presented) The activated foam according to claim 1, wherein said pharmaceutical agent is an anti-cancer agent.

4. (Original) The activated foam according to claim 3, wherein said pharmaceutical agent is a human-derived anticarcinogenic substance.

5. (Original) The activated foam according to claim 4, wherein said human-derived anticarcinogenic substance is an inhibitor of histone deacetylase (HDACI).

6. (Currently Amended) The activated foam according to claim 1, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

7. (Previously Presented) The activated foam according to claim 2, wherein said pharmaceutical agent is an anti-cancer agent.

8. (Previously Presented) The activated foam according to claim 7, wherein said pharmaceutical agent is a human-derived anticarcinogenic substance.

9. (Previously Presented) The activated foam according to claim 8, wherein said human-derived anticarcinogenic substance is an inhibitor of histone deacetylase (HDACI).

10. (Currently Amended) The activated foam according to claim 2, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

11. (Currently Amended) The activated foam according to claim 3, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

12. (Currently Amended) The activated foam according to claim 4, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

13. (Currently Amended) The activated foam according to claim 5, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

14. (Cancelled).

15. (Currently Amended) The activated foam according to claim 7, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

16. (Currently Amended) The activated foam according to claim 8, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

17. (Currently Amended) The activated foam according to claim 9, wherein said ~~cell is~~ cells are formed at a density of 20 to 30 cells/mm<sup>2</sup>.

18. (New) A method of increasing an effect of a pharmaceutical agent, comprising: contacting directly or indirectly with a human body, at the same time when said pharmaceutical agent is administered, an activated foam made of a natural or synthetic rubber or a synthetic resin, wherein said foam comprises cells with a closed-cell structure and contains a zirconium compound and/or a germanium compound.